UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000058276 |
|---|---|
| Receipt number | R000066619 |
| Scientific Title | Effects of wearing a home-use far-infrared circulation-promoting shirt on blood flow (Wear over underwear) : a randomized, double-blind, placebo-controlled, cross-over trial. |
| Date of disclosure of the study information | 2025/06/28 |
| Last modified on | 2025/06/25 14:25:34 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effects of wearing a home-use far-infrared circulation-promoting shirt on blood flow (Wear over underwear)
Acronym
RU study
Scientific Title
Effects of wearing a home-use far-infrared circulation-promoting shirt on blood flow (Wear over underwear) : a randomized, double-blind, placebo-controlled, cross-over trial.
Scientific Title:Acronym
Effects of wearing a home-use far-infrared circulation-promoting shirt on blood flow (Wear over underwear)
Region
| Japan |
Condition
Condition
Healthy adult
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To compare and evaluate the effect on blood flow when wearing clothes intended to improve symptoms such as fatigue and muscle stiffness by promoting blood circulation of far infrared rays.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
blood flow
Key secondary outcomes
Sublingual body temperature, body surface temperature, blood pressure, VAS
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Device,equipment |
Interventions/Control_1
Wearing test article A
Interventions/Control_2
Wearing test article B
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 30 | years-old | <= |
Age-upper limit
| 59 | years-old | >= |
Gender
Female
Key inclusion criteria
Healthy Japanese men and women
Key exclusion criteria
1. Pregnant women, those who are breastfeeding, or those who may become pregnant
2. Subjects taking drugs that affect hemodynamics
3. Subjects who are receiving treatment, medication, or lifestyle guidance from a doctor
4. Subjects who work night shifts or day and night shifts
5. Subjects with heart disease or hypertension
6. Subjects taking supplements that affect blood flow and coldness
7. Subjects undergoing hormone replacement therapy
8. Subjects whose test date is within 2 weeks from the most recent vaccination
9. Subjects with serious cerebrovascular disease, heart disease, liver disease, renal disease, digestive system disease, infectious disease requiring notification, etc.
10. Subjects who have participated in, or plan to participate in, other clinical studies that are affected by this study within one month prior to obtaining informed consent
11. Other subjects judged inappropriate by the principal investigator
Target sample size
16
Research contact person
Name of lead principal investigator
| 1st name | Takeshi |
| Middle name | |
| Last name | Kaneko |
Organization
Japan Clinical Trial Association
Division name
N.A.
Zip code
1600022
Address
5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo
TEL
0364574666
info@yakujihou.org
Public contact
Name of contact person
| 1st name | Takeshi |
| Middle name | |
| Last name | Kaneko |
Organization
Japan Clinical Trial Association
Division name
N.A.
Zip code
1600022
Address
5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo
TEL
0364574666
Homepage URL
info@yakujihou.org
Sponsor or person
Institute
Japan Clinical Trial Association
Institute
Department
Personal name
Funding Source
Organization
Relive Co.,Ltd
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Institutional Review Board of Pharmaceutical Law Wisdoms
Address
5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo
Tel
0364574911
master@yakujihou.net
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 06 | Month | 28 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2025 | Year | 03 | Month | 19 | Day |
Date of IRB
| 2025 | Year | 05 | Month | 22 | Day |
Anticipated trial start date
| 2025 | Year | 06 | Month | 28 | Day |
Last follow-up date
| 2025 | Year | 06 | Month | 29 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2025 | Year | 06 | Month | 25 | Day |
Last modified on
| 2025 | Year | 06 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066619
